Gateway Investment Advisers LLC bought a new position in PRA Health Sciences Inc (NASDAQ:PRAH) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 17,616 shares of the medical research company’s stock, valued at approximately $1,620,000.
A number of other large investors also recently made changes to their positions in PRAH. FMR LLC grew its position in PRA Health Sciences by 84.6% in the second quarter. FMR LLC now owns 2,295,675 shares of the medical research company’s stock worth $214,324,000 after acquiring an additional 1,051,810 shares in the last quarter. Swedbank bought a new stake in PRA Health Sciences in the third quarter worth $104,802,000. Frontier Capital Management Co. LLC bought a new stake in PRA Health Sciences in the third quarter worth $78,126,000. Bank of New York Mellon Corp lifted its stake in PRA Health Sciences by 44.2% in the second quarter. Bank of New York Mellon Corp now owns 2,197,004 shares of the medical research company’s stock worth $205,113,000 after purchasing an additional 673,202 shares during the last quarter. Finally, Vanguard Group Inc lifted its stake in PRA Health Sciences by 12.8% in the third quarter. Vanguard Group Inc now owns 5,811,972 shares of the medical research company’s stock worth $640,421,000 after purchasing an additional 658,191 shares during the last quarter. Institutional investors own 97.23% of the company’s stock.
Several analysts have weighed in on the stock. BidaskClub downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, December 27th. Evercore ISI assumed coverage on shares of PRA Health Sciences in a research note on Thursday, October 4th. They issued an “inline” rating and a $120.00 price target for the company. Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. ValuEngine downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, SunTrust Banks boosted their price target on shares of PRA Health Sciences to $120.00 and gave the stock a “buy” rating in a research note on Monday, November 5th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $112.56.
Shares of NASDAQ:PRAH opened at $101.65 on Friday. The stock has a market cap of $6.49 billion, a PE ratio of 31.77, a PEG ratio of 1.25 and a beta of 1.10. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 1.22. PRA Health Sciences Inc has a 12 month low of $79.20 and a 12 month high of $121.98.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, October 31st. The medical research company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.07 by $0.06. The firm had revenue of $717.60 million during the quarter, compared to the consensus estimate of $729.63 million. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The company’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.88 earnings per share. On average, equities analysts anticipate that PRA Health Sciences Inc will post 3.93 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Gateway Investment Advisers LLC Buys New Stake in PRA Health Sciences Inc (PRAH)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2019/01/20/gateway-investment-advisers-llc-buys-new-stake-in-pra-health-sciences-inc-prah.html.
PRA Health Sciences Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Article: What is a Roth IRA?
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.